Limor Cohen

Limor Cohen

Auto-generated profile, based on publicly available information

Limor Cohen

Harvard Medical School Boston MA 02115 USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 August 2018 in Chemical Reviews
Verified
Journal Article
Closed access
LCLimor Cohen
Limor Cohen
DWDavid R. Walt
David R. Walt

26 June 2020 in ACS Nano
Verified
Journal Article
Closed access
LCLimor Cohen
Limor Cohen
NCNaiwen Cui
Naiwen Cui
YCYamei Cai
Yamei Cai
PGPadric M. Garden
Padric M. Garden
XLXiang Li
Xiang Li
DWDavid R. Walt
David R. Walt

29 November 2018 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
XWXu Wang
Xu Wang
LCLimor Cohen
Limor Cohen
JWJun Wang
Jun Wang
DWDavid R. Walt
David R. Walt

18 September 2020 in Nature Biomedical Engineering
Verified
Journal Article
Closed access
PDF file
MNMaia Norman
Maia Norman
TGTal Gilboa
Tal Gilboa
AOAlana F. Ogata
Alana F. Ogata
AMAdam M. Maley
Adam M. Maley
LCLimor Cohen
Limor Cohen
DWDavid R. Walt
David R. Walt

12 September 2023 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
MTMartin Samuel Taylor
Martin Samuel Taylor
CWConnie Wu
Connie Wu
PFPeter C. Fridy
Peter C. Fridy
SZStephanie J. Zhang
Stephanie J. Zhang
YSYasmeen Senussi
Yasmeen Senussi
KBKathleen H. Burns
Kathleen H. Burns
Improved biomarkers are needed for early cancer detection, risk stratification, treatment selection, and monitoring treatment response. Although proteins can be useful blood-based biomarkers, many have limited sensitivity or specificity for these applications. Long INterspersed Element-1 (LINE-1) open reading frame 1 protein (ORF1p) is a transposable element protein overexpressed in carcinomas and high-risk precursors during carcinogenesis with negligible expression in normal tissues, suggesting ORF1p could be a highly specific cancer biomarker. To explore ORF1p as a blood-based biomarker, we engineered ultrasensitive digital immunoassays that detect mid-attomolar (10−17 mol/L) ORF1p concentrations in plasma across multiple cancers with high specificity. Plasma ORF1p shows promise for early detection of ovarian cancer, improves diagnostic performance in a multianalyte panel, provides early therapeutic response monitoring in gastroesophageal cancers, and is prognostic for overall survival in gastroesophageal and colorectal cancers. Together, these observations nominate ORF1p as a multicancer biomarker with potential utility for disease detection and monitoring. Significance: The LINE-1 ORF1p transposon protein is pervasively expressed in many cancers and is a highly specific biomarker of multiple common, lethal carcinomas and their high-risk precursors in tissue and blood. Ultrasensitive ORF1p assays from as little as 25 μL plasma are novel, rapid, cost-effective tools in cancer detection and monitoring. See related commentary by Doucet and Cristofari, p. 2502. This article is featured in Selected Articles from This Issue, p. 2489

1 June 2020 in Analytica Chimica Acta
Verified
Journal Article
Closed access
TGTal Gilboa
Tal Gilboa
PGPadric M. Garden
Padric M. Garden
LCLimor Cohen
Limor Cohen